Pub. Date : 2010 Oct
PMID : 20840481
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | The primary endpoint, event rate of biopsy-proven acute rejection (BPAR) at 24 weeks, was 33.7% for tacrolimus BID versus 36.3% for tacrolimus QD (Per-protocol set; p = 0.512; treatment difference 2.6%, 95% confidence interval -7.3%, 12.4%), falling within the predefined 15% noninferiority margin. | Tacrolimus | BH3 interacting domain death agonist | Homo sapiens |
| 2 | Twelve-month patient and graft survival was 90.8% and 85.6% for tacrolimus BID and 89.2% and 85.3% for tacrolimus QD. | Tacrolimus | BH3 interacting domain death agonist | Homo sapiens |